Leiolizumab

N/A

Report date: 2024/12/30 10:32:32

Base Information

Drug NameLeiolizumab

Drug Alias NameALTB-268AbGn-168H2AbGn-268AbGn 168H2

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionP-selectin glycoprotein ligand-1 agonistsApoptosis stimulantsT lymphocytes inhibitors

TargetsP-selectin glycoprotein ligand-1

Therapy Area/IndicationsColitis, UlcerativeArthritis, Psoriatic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesPuerto Rico

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAltrubio Inc

China Registration ClassN/A

Active CompaniesAltrubio Inc

Inactive CompaniesN/A

Active IndicationsColitis, UlcerativeArthritis, Psoriatic

Inactive IndicationsN/A

ATC CodeN/A